LB1256 TRIV-509, A Dual Inhibitor of KLK5 and KLK7, Rapidly Improves Barrier Integrity and Markers of Epidermal Differentiation in Atopic Dermatitis Skin Explants
July 2025
in “
Journal of Investigative Dermatology
”
TLDR TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
The study investigates the effects of TRIV-509, a dual inhibitor of KLK5 and KLK7, on atopic dermatitis (AD) skin explants. KLK5 and KLK7 are serine proteases that are dysregulated in AD, contributing to impaired barrier integrity and inflammation. In a small study involving 3 patients with AD, TRIV-509 treatment significantly reduced epidermal thickness, parakeratosis, and cell proliferation, while increasing DSG1+ cells in the epidermis. These findings suggest that TRIV-509 rapidly improves barrier integrity and epidermal differentiation, indicating its potential as a therapeutic option for AD.